News | September 17, 2010

Data presented on Xience V, Abbott's vascular pipeline

September 17, 2010 - The Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) symposium, to be held Sept. 21- 25, will feature presentations on Xience V data.

Highlights include late-breaking two-year data from SPIRIT IV, one of the largest randomized, head-to-head clinical trials between two drug eluting stents - Abbott's Xience V Everolimus Eluting Coronary Stent System and Boston Scientific's Taxus Express Paclitaxel-Eluting Coronary Stent System. In addition, Abbott will present data on two key pipeline products: the MitraClip system, an investigational device in the United States; and the bioresorbable vascular scaffold (BVS), currently under clinical investigation outside the United States.

Key presentations are as follows (all times are Eastern):

SPIRIT IV: Two-year results from SPIRIT IV will be presented by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the first late-breaking clinical trials session at 11 a.m. in the Main Arena on Thursday, Sept. 23. SPIRIT IV is one of the largest randomized clinical trials ever conducted that compares two drug eluting stents.
The study enrolled 3,690 patients - including more than 1,000 patients with diabetes. Dr. Stone is the principal investigator of the SPIRIT IV trial.

SPIRIT III: Four-year results from SPIRIT III will be presented during the Scientific Symposia starting at 1 p.m. on Wednesday, Sept. 22. SPIRIT III is a prospective, multi-center, randomized, single-blind, controlled clinical trial comparing XIENCE V to TAXUS in 1,002 patients (669 XIENCE V patients and 333 TAXUS patients) with either one or two de novo coronary artery lesions.

Xience V USA: One-year results from Xience V USA, including subset data, will be presented during the Scientific Symposia starting at 3:30 p.m. on Wednesday, Sept. 22. Xience V USA is a post-market, real-world, single-arm registry evaluating outcomes in more than 5,000 Xience V patients based in the U.S., with follow-up out to five years. Subset data presented at TCT will include information on patient quality of life after receiving a Xience V stent and data on the safety and efficacy of Xience V in real-world patients with acute myocardial infarction.

EVEREST II: During the Scientific Symposia starting at 3:30 p.m. on Wednesday, Sept. 22, a number of presentations will review new data from EVEREST II, the landmark trial of the MitraClip system, a catheter-based device for mitral valve repair. In addition, the MitraClip system will be highlighted during the "Hottest Topic of 2010: Transcatheter Valve Therapy" session starting at 9:30 a.m. on Thursday, Sept. 23, and the "Best of the Best TCT 2010 Abstracts" starting at 3:16 p.m. on Friday, Sept. 24. The MitraClip system received CE Mark in March 2008. In the U.S., the MitraClip system is limited by federal law to investigational use only and is not available for sale. The MitraClip system is currently under review for approval by the U.S. Food and Drug Administration.

ABSORB: Nine-month data on 45 patients and six-month data on all 101 patients from the second phase of ABSORB will be presented on Wednesday, Sept. 22. The ABSORB trial is evaluating Abbott's bioresorbable vascular scaffold (BVS), which aims to restore blood flow by opening a clogged vessel and providing support until it is healed. Once the vessel can remain open without the extra support, the BVS is designed to be slowly metabolized and eventually resorbed by the body. Abbott's BVS device is under clinical investigation outside the U.S. The device is currently in development at Abbott Vascular and not available for sale.

Abbott's Xience V drug-eluting stent is marketed in the U.S., Europe, Japan and other international markets.

For more information: www.xiencev.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init